(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29±³À°ÀÏÀÚ : 2022-04-29
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ
´ã´çÀÚ : ¹Ú¼Ò¹Î
¿¬¶ôó : 02-398-5055
À̸ÞÀÏ :
office@kscpt.org ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¸¶ÃëÅëÁõÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã ±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í ¿Â¶óÀÎ Âü¼® : Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 2¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 10¸¸¿ø, ºñȸ¿ø Çлý 5¸¸¿ø ÇöÀåÂü¼® : Á¤È¸¿ø 7¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 12¸¸¿ø, ºñȸ¿ø Çлý 8¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 13:00~13:40 Special lecture : Facts and Misconceptions about Aducanumab Approval Yaning Wang(Createrna Science and Technology)
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 13:40~14:10 Model guided dose escalation in oncology Phase 1 trial ±èÀ翬(Novartis Institutes for Biomedical Research (Cambridge MA USA))
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 14:10~14:40 Exposure-response relationship for current and future drug development ¿ÀÀ缺(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 14:40~15:10 Recent advances in exposure-response relationship in drug development ±èÁ¾·ü(ÀÎÁ¦´ë ºÎ»ê¹éº´¿ø)
Åä·Ð 04-29 ¿Â¶óÀÎ 15:10~15:30 Åä·Ð ()
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 15:30~16:00 Exposure-Response in Cancer: Starting from Genomics ±è±ÔÇ¥(¿ï»ê´ëÇб³)
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 16:00~16:30 Experiences to Characterize Exposure-Response Relationship for Various Therapeutics using Modeling and Simulation: Advantages and Challenges ÇѼºÇÊ(°¡Å縯´ëÇб³)
±³À°½Ã°£ 04-29 ¿Â¶óÀÎ 16:30~17:00 Exposure-Response RelationshipÀ» ÀÌ¿ëÇÑ ½Å¾à°³¹ß °æÇè ÀÌÁöÀº(LG »ý¸í°úÇÐ)
Åä·Ð 04-29 ¿Â¶óÀÎ 17:00~17:20 Åä·Ð ()